All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld Perspectives » Biotech’s Emerging Giant

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Biotech’s Emerging Giant

May 24, 2011
By Lynn Yoffee
No Comments

While attending the China track at this year’s J.P. Morgan conference in January I sat next to a gentleman who was smiling as he scanned the jam-packed penthouse meeting room. Shooting him a questioning glance, he responded with “last year I attended there were five people here.” While I find it hard to believe a session on China was poorly attended, even a year ago, biotech and pharma executives were noticeably shoulder to shoulder, jockeying for position just a few months ago. Intensity over the Chinese market has certainly ramped up, to say the least.

As company after Chinese company pitched and presented, the Q&A at the end of each session seemed to steer away from the usual grilling about the companies’ worth and pipes. Instead, questions were focused on how to get a toehold in China. Where to start? How to deal with the government? Should we go it alone or partner with existing Chinese companies?

A few weeks ago a contingent of U.S. executives, led by the Biotechnology Industry Organization’s President and CEO Jim Greenwood, visited China. It was a sort of pregame show in advance of BIO’s first China International Partnering Conference in October in Shanghai. The execs came home awestruck. BioWorld Today’s Tom Wall wrote about their impressions from that visit in a new series dubbed Biotech’s Emerging Giant, with the first article found here: http://bit.ly/k8kcJ2

Joshua Boger, founder of Vertex Pharmaceuticals Inc., of Cambridge, Mass. visited a manufacturing site for starting materials for the company’s just-approved hepatitis C drug Incivek (telaprevir), and declared the facility to be so immaculate and well prepared that “You can eat off the floor. Everything over there is so much better coordinated.”

In part II of the series published today, Wall interviews executives who are advising slow comers to light a fire under their China strategies . . . if a company expects to be around in the next five to 10 years.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing